- Home
- NRDS vs PHAR Comparison
NRDS vs PHAR Comparison
Compare NRDS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | PHAR |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRDS | PHAR |
|---|---|---|
| Price | $10.13 | $16.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $15.83 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 927.9K | 32.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 353.33 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $687,600,000.00 | N/A |
| Revenue This Year | $22.09 | $25.19 |
| Revenue Next Year | $7.18 | $4.47 |
| P/E Ratio | ★ $10.87 | $3,041.22 |
| Revenue Growth | ★ 14.71 | N/A |
| 52 Week Low | $7.55 | $7.50 |
| 52 Week High | $16.24 | $21.34 |
Technical Indicators
Market Signals| Indicator | NRDS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 46.85 |
| Support Level | $9.07 | $15.26 |
| Resistance Level | $12.64 | $16.48 |
| Average True Range (ATR) | 0.63 | 0.68 |
| MACD | -0.09 | -0.22 |
| Stochastic Oscillator | 28.67 | 26.23 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.